Back to Journals » Biologics: Targets and Therapy » Volume 2 » Issue 1

The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn's disease - An interview with David A Schwartz, 13 June 2007

Total article views   HTML views PDF downloads Totals
7,485 Dovepress* 7,485+ 1,588 9,073
Totals 7,485 1,588 9,073
*Since 7 March 2008
+Since July 2016

View citations on Google Scholar